AnaptysBio (ANAB) was given a new $85.00 price target by Leerink Partners.
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio [Yahoo! Finance]
Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim
AnaptysBio (ANAB) had its price target lowered by Barclays PLC from $79.00 to $63.00. They now have an "overweight" rating on the stock.
AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics [Seeking Alpha]